Healthcare
Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered into an exclusive multi-country commercial supply agreement with Fosun Diagnostics for the Company's ImmuneSelect research-use immune profiling product line. The agreement covers six Southeast Asian markets, including Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia, and establishes a framework for immediate product s
About this update from Virax Biolabs Group Limited
LONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered into an exclusive multi-country commercial supply agreement with Fosun Diagnostics for the Company's ImmuneSelect research-use immune profiling product line. The agreement covers six Southeast Asian markets, including Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia, and establishes a framework for immediate product supply under purchase orders, supporting near-term potential revenue opportunities and regional commercial expansion. ImmuneSelect is Virax's commercially available research-use-only ("RUO") immune profiling product line and is distinct from ViraxImmune™, the Company's in-development diagnostic platform currently progressing through clinical and regulatory development. Virax believes the agreement represents a significant commercial milestone for its ImmuneSelect platform, providing access to multiple Southeast Asian markets through a leading regional diagnostics organization. The framework is designed to support phased commercial expansion, including additional product offerings, higher-volume supply arrangements, and potential OEM or private-label arrangements. Fosun Diagnostics is the core entity of the diagnostics business under Fosun Medtech, a division of Fosun Pharma. Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group with operations spanning pharmaceuticals, medical technologies, diagnostics and healthcare services. Fosun Pharma reported 2025 revenue of RMB41.662 billion, approximately US$5.8 billion. Virax believes Fosun Diagnostics provides a commercially established partner for evaluating and expanding the reach of ImmuneSelect across the ASEAN region. KEY HIGHLIGHTS:
View stock analysis, news, and events for Virax Biolabs Group Limited